sellModerate cluster of 410b5-1 plan
Sujal Shah sold $1.0M of CBAY
Chief Executive Officer at CymaBay Therapeutics, Inc.. 64,863 shares at an average of $15.89, traded Nov 13, 2023, filed Nov 14, 2023.
Warning score
40Value
$1.0M
64,863 shares
Holdings after
171,301
-30% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +25RoleCEO
- +25Trade size$1.0M at market
- +10Share of holdings soldSold 30% of holdings
- +15Cluster4 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001062993-23-020835, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 13, 2023 | MOption exercise Common Stock10b5-1 | +44,008 | $5.00 | $220k | 215,309 | Nov 14, 2023 |
| Nov 13, 2023 | SOpen-market sale Common Stock10b5-1 | -44,008 | $15.89 | $699k | 171,301 | Nov 14, 2023 |
| Nov 13, 2023 | MOption exercise Common Stock10b5-1 | +20,855 | $5.00 | $104k | 192,156 | Nov 14, 2023 |
| Nov 13, 2023 | SOpen-market sale Common Stock10b5-1 | -20,855 | $15.89 | $331k | 171,301 | Nov 14, 2023 |
| Nov 13, 2023 | MOption exercise Employee Stock Option (right to buy)derivative10b5-1 | -31,036 | $0.00 | $0 | 31,036 | Nov 14, 2023 |
| Nov 13, 2023 | MOption exercise Stock Appreciation Rightderivative10b5-1 | -12,972 | $0.00 | $0 | 12,973 | Nov 14, 2023 |
| Nov 13, 2023 | MOption exercise Employee Stock Option (right to buy)derivative10b5-1 | -20,855 | $0.00 | $0 | 20,856 | Nov 14, 2023 |
Related signals
Other insiders at CymaBay Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 33Weak | CymaBay Therapeutics, Inc. | Charles McWherter President of R&D | $243k 11,332 shares | -57% | |
| 25Weak | CymaBay Therapeutics, Inc. | Paul T Quinlan General Counsel | $110k 5,000 shares | -100% | |
| 32Weak | CymaBay Therapeutics, Inc. | Daniel Menold Vice President, Finance | $473k 21,497 shares | -215% | |
| 25Weak | CymaBay Therapeutics, Inc. | Janet Dorling director | $120k 6,000 shares | -100% | |
| 40Moderate | CymaBay Therapeutics, Inc. | Sujal Shah Chief Executive Officer | $1.3M 64,865 shares | -28% | |
| 24Weak | CymaBay Therapeutics, Inc. | Paul T Quinlan General Counsel | $87k 5,000 shares | -100% | |
| 22Weak | CymaBay Therapeutics, Inc. | Charles McWherter President of R&D | $207k 11,342 shares | -43% | |
| 25Weak | CymaBay Therapeutics, Inc. | Janet Dorling director | $107k 7,000 shares | -100% | |
| 16Weak | CymaBay Therapeutics, Inc. | Paul T Quinlan General Counsel | $69k 5,000 shares | -100% | |
| 27Weak | CymaBay Therapeutics, Inc. | Charles McWherter President of R&D | $306k 21,743 shares | -59% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.